Table 1 VEN combined with chemotherapy drugs for R/R AML

Regimen

VEN + CPX-351

VEN + CAG

VEN + HAM

VEN + selinexor + FLA(G)

VEN + MTO + HHT + olverembatinib

Study type

Phase Ib/II

N/A

Phase-I/II

Phase I

N/A

NCT number

NCT03629171

N/A

NCT04330820

NCT04898894

N/A

Study period

2018–2022

2016–2023

2020–2023

N/A

N/A

Patients number

33

37

38

14

18

Male

13 (39.4%)

24 (64.8%)

N/A

9 (64.3%)

9 (50.0%)

Age range (years)

26–72

18–68

26–74

3–17

0.3–13

Median prior lines of therapies

1 (1–7)

N/A

N/A

N/A

N/A

Prior exposure to VEN

19 (57.6%)

N/A

N/A

N/A

N/A

Response rate

ORR 45%,CR/CRi 39%

CRc 78.4%

CR/CRi 81.6%

CR/CRi 41.7

ORR 94.4%,CR/CRi 72.2%

Grade ≥ 3 AEs

Infections 45%

febrile neutropenia 67.6%

febrile neutropenia ≥ 10%

febrile neutropenia 16.7%

Neutropenia 100%

Follow-up (months)

20.7

N/A

N/A

N/A

N/A

Survival

Median OS 6.4 months

The one-year OS 78.4%

N/A

N/A

The 8-month mean EFS 60.1% and the OS 100%